Ocugen NASDAQ: OCGN is preparing for three planned biologics license application, or BLA, submission

Ocugen is advancing three gene therapy programs—OCU400, OCU410ST, and OCU410—targeting major unmet n

Shares of Ocugen are remaining flat Thursday morning as investors continue to weigh disappointing in

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy

Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market

Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regula

Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company

The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in g

MALVERN, Pa., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: O

MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN),

Shares of Ocugen, Inc. (NASDAQ: OCGN - Get Free Report) have earned a consensus rating of "Moderate

Ocugen NASDAQ: OCGN is positioning its ophthalmology gene therapy portfolio around treatments for in

OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs

Ocugen NASDAQ: OCGN said its second quarter marked progress across its late-stage ophthalmology pipe

Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript

Ocugen (OCGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate

Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.07) per share which missed the analyst consens

Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) c

MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN),

RMAT designation is intended to help expedite development of new regenerative medicines that have po

MALVERN, Pa, July 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCG

MALVERN, Pa. , July 28, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN)

Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRo

Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones R

Ocugen NASDAQ: OCGN outlined plans to advance three late-stage retinal disease programs, with compan

MALVERN, Pa. , July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN)

Canaccord Genuity analyst Whitney Ijem maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the p

Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which missed the analyst consens

Dow futures up 100 pts. Shares of GeneDx Holdings (WGS) down 39.2% after cutting FY26 sales guidance

Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology l

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy

Ocugen stock falls after Phase 2 OCU410 data for dry AMD trails interim results, despite lesion redu

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth

Canaccord Genuity analyst Whitney Ijem initiates coverage on Ocugen (NASDAQ:OCGN) with a Buy rati

Ocugen shares are surging Wednesday afternoon after Oppenheimer analyst Leland Gershell initiated co

Dow falls 200+ points as Serve Robotics Inc (NASDAQ: SERV) shares rise 16.2% on better-than-expected

Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst r

Oppenheimer analyst Leland Gershell initiates coverage on Ocugen (NASDAQ:OCGN) with a Outperform

Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which met the analyst consensus

Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therap

Ocugen shares sank sharply Wednesday after the biotech company announces a $22.5 million underwritte

Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positi